Clinical Trials

MONITOR-Breast: Monitoring cell-free tumor DNA as a marker of recurrence in Breast Cancer

ClinicalTrials.gov Identifier

ClinicalTrials.gov registration not required

Principal Investigator

Marcela Mazo Canola MD

For more information about this study
View Details

About This Study

This is a prospective, observational study designed to evaluate the clinical validity of Myriad Genetics’ MRD test in patients diagnosed with breast cancer. It is expected that enrollment will be split between the different breast cancer subtypes defined by immunohistochemistry (HR+/HER2-, HER2+ (HR+ and HR-), TNBC) and according to BINV-A of National Comprehensive Cancer Network guidelines with ER+ status used here as >10% of nuclei staining.